Abstract
Molecular imaging (mainly PET and MR imaging) has played important roles in gynecologic oncology. Emerging MR-based technologies, including DWI, CEST, DCE–MR imaging, MRS, and DNP, as well as FDG-PET and many novel PET radiotracers, will continuously improve practices. In combination with radiomics analysis, a new era of decision making in personalized medicine and precisely guided radiation treatment planning or real-time surgical interventions is being entered into, which will directly impact on patient survival. Prospective trials with well-defined endpoints are encouraged to evaluate the multiple facets of these emerging imaging tools in the management of gynecologic malignancies.
| Original language | English |
|---|---|
| Pages (from-to) | 289-299 |
| Number of pages | 11 |
| Journal | PET Clinics |
| Volume | 13 |
| Issue number | 2 |
| DOIs | |
| State | Published - 04 2018 |
Bibliographical note
Publisher Copyright:© 2017 Elsevier Inc.
Keywords
- Cervical cancer
- Endometrial cancer
- MR imaging
- Molecular imaging
- Ovarian cancer
- PET
- Radiomics
- Vulvar cancer